SEC Filing · SCHEDULE 13D/A
CollPlant Biotechnologies Ltd
CLGNNASDAQEQUITYCurrent
SEC Filing
Company context
We are a regenerative and aesthetic medicine company focused on medical aesthetics and 3D bioprinting of tissues and organs. Our products are based on our recombinant human collagen (rhCollagen) that is produced in genetically engineered tobacco plants using our proprietary technology. These products address indications for the diverse fields of tissue repair and aesthetics, and are ushering in a new era in regenerative and aesthetic medicine.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗